Page 174 - CW E-Magazine (24-9-2024)

Special Report

factor in the segment growth. The high fluenced the growth of this therapeutic diseases. The infectious disease treat-
demand for novel cancer therapies and area. Additionally, the introduction of ment market was valued at $72.5-bn
the increasing complexity of oncology novel drug delivery technologies, such in 2021 and is predicted to grow to
clinical trials have led to a significant as nasal sprays, has been identified to $106.4-bn by 2026, at a CAGR of
focus on oncology research. With new be the key contributor to the segment 8.2%. The biggest driver for this growth
regulatory guidance emerging and dif- revenue. in demand is the vaccines or treat-
ferent alternatives from the standard ments for SARS-CoV-2 virus and
maximum tolerated dosing in proving a Clinical CROs that are involved in other infectious diseases.
treatment’s efficacy and toxicity, there clinical trials focused on respiratory
are excellent opportunities for CROs diseases, offering services such as res- Central Nervous System (CNS)
specialized in Biostatistics. piratory function testing, bronchosco- disorders
pies, and specialized assessments rela- The prevalence of CNS disorders
CROs capable of providing specia- ted to clinical endpoints for evaluating such as Alzheimer’s disease, Parkin-
lized services in oncology, including treatment efficacy will have competi- son’s disease, and mental health disor-
patient recruitment, biomarker analysis, tive edge over the conventional CROs. ders has led to a growing emphasis on
imaging services will have a competi- research in this therapeutic area. CROs
tive edge. More than 900 next-gene- Rare diseases are offering services in CNS-focused
ration biotherapeutics are now in the Rare diseases, also known as orphan clinical trials, including patient recruit-
R&D pipeline, with increased activity diseases, affect a small percentage of ment, cognitive assessments, neuroim-
in CAR T and NK cell therapies as well the population but pose significant aging, and biomarker analysis. The
as gene editing and nucleic acid vac- challenges in terms of diagnosis and development of novel therapies for
cines. More than 40% of next-genera- treatment. With an estimated 300-mn CNS disorders remains a priority for
tion biotherapeutics in development in people worldwide affected by rare many pharmaceutical companies.
2022 were for oncology, bringing great diseases, the demand for treatments is
promise for cancer treatment. growing. The global rare disease treat- Immunology and autoimmune
ment market was valued at $195-bn diseases
Respiratory in 2023, which has resulted in a rising The field of immunology and auto-
Respiratory systems segment ac- demand for CROs to support sponsors immune diseases has seen significant
counted for one of the largest shares of of clinical trials. There are several rea- advancements in recent years. CROs
over 14% of the global pharmaceutical sons for this trend including regulatory are supporting research in areas such
revenue in 2022. Lung diseases are incentives, advancements in genomics, as rheumatoid arthritis, multiple scle-
responsible for over 700,000 hospital precision medicines, patient advocacy rosis, and inflammatory bowel disease.
admissions and over 6-million inpatient groups, and the increased emergence Services in this therapeutic area include
bed-days in the UK per year. An esti- of biotech, particularly in the US mar- patient recruitment, immunogenicity
mated 1.2-million people are living with ket. Many CROs are expanding their assessments, cytokine profiling, and
diagnosed COPD in the UK. As per the capabilities and expertise in conducting specialized assays for measuring
2019 report of the National Health Por- rare disease trials to meet this demand. immune response.
tal of India, 41,996,260 cases and 3,740 CROs are increasingly supporting
deaths from respiratory infections were clinical research in rare diseases, provi- Cardiovascular diseases
recorded across India in 2018. India ding expertise in patient recruitment, Cardiovascular diseases, including
contributes to 18% of the global popu- trial design, regulatory strategies, and heart disease and stroke, remain lead-
lation with severe acute respiratory patient registries. In India, top pharma ing causes of mortality worldwide.
infections (SARI) as one of the promi- sponsored trials for orphan disease has CROs are involved in cardiovascular
nent causes of mortality in children >5 increased by 4% in India in the last research, providing services such as
years of age. The high incidence of res- decade (2010-21), primarily led by patient recruitment, cardiovascular im-
piratory disorders, such as bronchitis, global companies like Novartis, Sanofi, aging, electrocardiography, and moni-
tuberculosis, Chronic Obstructive Pul- and AstraZeneca. toring of cardiovascular endpoints
monary Diseases (COPD), and asthma, in clinical trials. The development of
coupled with increasing cases of drug Infectious diseases innovative therapies for cardiovascular
resistance are of significant interest in The recent COVID-19 pandemic diseases continues to be an area of
pharmaceutical research and it has in- has increased the focus on infectious interest for pharmaceutical companies.

174 Chemical Weekly September 24, 2024

Contents Index to Advertisers Index to Products Advertised